Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan
BMC Medical Ethics · 2024
DOI: 10.1186/s12910-024-01014-2 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift BMC Medical Ethics, 2024. Verfasst von Anju Murayama und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba ward, Sendai City, Miyagi, 980-0872, Japan. anju.murayama.s8@dc.tohoku.ac.jp. Hauptthemen laut MEDLINE: Allergists, Pandemics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Financial interactions between pharmaceutical companies and physicians lead to conflicts of interest. This study examines the extent and trends of non-research payments made by pharmaceutical companies to board-certified allergists in Japan between 2016 and 2020.
Methods
A retrospective analysis of disclosed payment data from pharmaceutical companies affiliated with the Japanese Pharmaceutical Manufacturers Association was conducted. The study focused on non-research payments for lecturing, consulting, and manuscript drafting made to board-certified allergists from 2016 to 2020. We performed descriptive analyses on payment data. Trends were analyzed using generalized estimating equation models.
Results
Of the 3,943 board-certified allergists, 2,398 (60.8%) received non-research payments totaling $43.4 million over five years. Lecturing fees comprised 85.7% ($37.2 million) of the total payment amounts. For allergists who received at least one payment, the median amount per allergist was $3,106 (interquartile range: $966 – $12,124), in contrast to a mean of $18,092 (standard deviation: $49,233) over the five-year span. The top 1% and 10% of these allergists accounted for 20.8% and 68.8% of all non-research payments, respectively. The annual payment amounts significantly increased by 7.2% annual increase (95% CI: 4.4 – 10.0%, p < 0.001) each year until 2019, but saw a significant decrease in 2020 amid the COVID-19 pandemic.
Conclusion
The majority of allergists received non-research payments, with a notable concentration among a small group. Payments increased annually until the pandemic’s onset, which coincided with a substantial decrease. Further research is needed to explore the implications of these financial interactions on clinical practice and patient care in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba ward, Sendai City, Miyagi, 980-0872, Japan. anju.murayama.s8@dc.tohoku.ac.jp.
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. anju.murayama.s8@dc.tohoku.ac.jp.
- Higashi Totsuka Memorial Hospital, Yokohama City, Kanagawa, Japan.
Zitieren
APA
Murayama, A., & Senoo, Y. (2024). Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan. BMC Medical Ethics. https://doi.org/10.1186/s12910-024-01014-2
Vancouver
Murayama A, Senoo Y. Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan. BMC Medical Ethics. 2024. doi:10.1186/s12910-024-01014-2
BibTeX
@article{Murayama2024,
author = {Murayama, Anju and Senoo, Yuki},
title = {Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan},
journal = {BMC Medical Ethics},
year = {2024},
doi = {10.1186/s12910-024-01014-2}
}
EUVIMED